ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO334

Association of uTWEAK Levels with Histological Findings, Endothelial and Tubulointerstitial Markers (VEGF/VCAM-1, TGFβ) in Patients with Lupus Nephritis (LN)

Session Information

Category: Glomerular Diseases

  • 1201 Glomerular Diseases: Fibrosis and Extracellular Matrix

Authors

  • Reyes, Fabiola, IMSS, México, Ciudad de México, Mexico
  • Toledo, Germain, IMSS, México, Ciudad de México, Mexico
  • Soto, Virgilia, INC Ignacio Chavez, Mexico City, Mexico
  • Perez-Navarro, L. Monserrat, Hospital General de México Dr. Eduardo Liceaga, México, Mexico
  • Valdez-Ortiz, Rafael, Hospital General de Mexico, Mexico City, DISTRITO FEDERAL, Mexico
Background

Urinary TWEAK levels (uTWEAK) are a sensitive and specific biomarker in the evaluation of LN in patients with SLE, however, its association with histological findings and expression of endothelial and tubulointerstitial lesion marker is unknown.

Methods

Cross-sectional study. We determinate the degree of association between uTWEAK with histological findings and markers of endothelial lesion (VEFG and VCAM-1) and tubulointerstitial (TFGβ) in patients with LN that have not been received immunosuppressive treatment. Non parametric statistics, logistic regression model, 95%CI, and p <0.05 were performed as statistically significant.

Results

Thirty-six patients were evaluated, 83.3% (30) were female. With predominance of histological class IV+V (41.6%). In the histological findings, 63.8% had a low chronicity index (<6 points), the activity index (AI) was 50% >12 points. The uTWEAK according to the histological class did not show statistically significant differences. In 72.2% of the patients, VEGF at glomerular was ≥50% and at the arteriolar level, 77.8% of the patients presented deposits of ≥50%. In Figure 1, the correlation between the histological findings and the endothelial and tubolointerstitial biomarkers is observed. Although, uTWEAK was not associated significantly with AI and arteriolar VEGF deposits (OR 4.18, p= 0.223 and 11.298, p= 0.120), effect size (d-Cohen) was of 0.78 and 1.33 respectively.

Conclusion

The uTWEAK represents a sensitive and specific biomarker in the evaluation of LN in patients with SLE, however, his expression does not seem to distinguish between the different classes of LN; an association was found with AI and VEGF. It is relevant to evaluate the outcome of the patients and to establish if the markers evaluated have an impact on the prognosis of the patients.